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irinotecan-based chemotherapy regimens, was demonstrated in randomized studies in the first-and subsequent-line treatments of metastatic colorectal cancer (mCRC) and was shown to be restricted to patients with KRAS wild-type tumors [1, [10] [11] [12] [13] [14] .
The selection of a weekly cetuximab dosing regimen was based on pharmacokinetic and safety data from early dosefinding studies. Cetuximab clearance equating to full-receptor occupancy was saturated at weekly doses >200 mg/m 2 [15] , thus a weekly regimen comprising an initial 2-h infusion of 400 mg/m 2 followed by weekly 1-h infusions of 250 mg/m 2 was adopted for subsequent phase II and III studies. The standard first-line chemotherapy regimens approved for use in combination with cetuximab in KRAS wild-type mCRC are, oxaliplatin plus infusional 5-fluorouracil (5-FU) and folinic acid (FOLFOX), and irinotecan plus infusional 5-FU and leucovorin (FOLFIRI), which are administered on an every second week basis [11, 13] . The synchronization of the administration of cetuximab with the every second week schedule commonly implemented for chemotherapy would therefore improve the convenience of treatment of the patient and most likely reduce the overall cost of treatment of the health care provider.
The pharmacokinetic data for cetuximab suggest the feasibility of every second week dosing [16] [17] [18] . This was further investigated in a two part phase I dose-escalation study in patients with previously untreated mCRC [19] . Part 1 comprised patients receiving 6 weeks of cetuximab monotherapy (every second week) dose-escalation, and in part 2, patients received cetuximab (at the same dose/schedule as in the monotherapy phase) in combination with FOLFIRI. The maximum tolerated dose was not achieved, and the authors reported that cetuximab every second week could be safely administered at doses of between 400 and 700 mg/m 2 with 500 mg/m 2 being the recommended dose for future study. A number of studies confirmed that cetuximab 500 mg/m 2 every second week in combination with irinotecan-based chemotherapy was safe and effective when administered to patients with chemorefractory disease [20] [21] [22] [23] [24] [25] [26] .
The addition of a standard weekly regimen of cetuximab to first-line FOLFOX4 demonstrated a significant improvement in outcome in patients with KRAS wild-type mCRC in the OPUS study [13] . Therefore, investigation of the synchronization of the cetuximab regimen with oxaliplatin-based chemotherapy appears worthwhile in this setting. In this Central European Co-operative Oncology Group (CECOG)-sponsored randomized study, first-line FOLFOX4 plus cetuximab every second week was compared with FOLFOX4 plus weekly cetuximab in the treatment of patients with KRAS wild-type mCRC.
patients and methods

patient eligibility
Patients were ≥18 years of age with histologically confirmed adenocarcinoma of the colon or rectum, mCRC not suitable for curativeintent resection and with signed written informed consent. At the start of the study, a growing number of reports [27] [28] [29] [30] , since confirmed [11, 13] , suggested that patients with KRAS mutant mCRC did not benefit from treatment with cetuximab. Following a protocol amendment (5 March 2008) , only patients with KRAS wild-type tumors were eligible for randomization.
Other eligibility criteria included: the availability of tumor samples for the assessment of KRAS mutation status (after protocol amendment) and EGFR expression; the presence of at least one lesion measurable unidimensionally by computed tomography (CT) or magnetic resonance imaging (MRI); Karnofsky performance status (PS) of ≥80%, with adequate organ function. Patients were excluded if they had brain metastases; had received previous chemotherapy for metastatic disease ( prior adjuvant chemotherapy was allowed if the chemotherapy treatmentfree interval was >6 months); had undergone surgery (excluding diagnostic biopsy) or irradiation within 4 weeks before study entry; were receiving concurrent chronic systemic immune therapy, chemotherapy or hormone therapy not indicated in the study protocol; had received any investigational agents within 4 weeks before entry or previous exposure to EGFR-pathway targeting therapy; had coronary artery disease or a history of myocardial infarction within the last 12 months; had acute or subacute intestinal occlusion or history of inflammatory bowel disease; had preexisting neuropathy >grade 1; known grade 3 or 4 allergic reaction to any of the components of the treatment; had any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix; were pregnant or lactating.
The study protocol was approved by the independent ethics committees and the local authorities and was conducted in accordance with the ethical principles of the Declaration of Helsinki. followed by an iv infusion of 600 mg/m 2 over 22 h on day 1 and day 2) every 2 weeks. Cetuximab and FOLFOX4 were continued until disease progression, unacceptable toxicity or patient withdrawal of consent. In the case of FOLFOX4, this was for a maximum of 13 cycles, and then singleagent cetuximab could be continued as a maintenance therapy.
study design and treatment
assessments
The primary end point was the objective response rate (ORR). Secondary end points included progression-free survival (PFS), disease control rate (DCR) and overall survival (OS). Treatment safety profiles were also determined. Best overall tumor response and PFS rates were assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST version 1). CT or MRI scans were carried out every 8 weeks. Objective responses (complete or partial response) were confirmed ≥4 weeks after primary response assessment.
Tumor DNA, extracted from formalin-fixed, paraffin-embedded tissue, was screened for KRAS mutations (codons 12 and 13) using a mutation detection kit (DxS Ltd., Manchester UK), and for BRAF mutations (V600E) by pyrosequencing (PyroMark Therascreen BRAF Kit IVD, Qiagen GmbH, Austria); mutation analysis was carried out centrally at the Department of Pathology at the Medical Universities of Vienna and Graz, respectively.
Adverse events (AEs) were assessed using the National Cancer Institute Common Terminology Criteria for AEs (version 3.0) and coded using the Medical Dictionary for Regulatory Activities (MedDRA; version 13.1).
statistical methods and considerations
The main analysis of study end points was carried out on the KRAS wildtype population, which comprised randomized patients with KRAS wildtype mCRC who received at least one dose of study treatment. Stratification factors in the efficacy analysis were the number of organs involved (1-2 versus >2) and prior adjuvant/neoadjuvant therapy (no, yes with oxaliplatin and yes without oxaliplatin).
The study was not powered to establish non-inferiority of arm 2 versus 1, but aimed at the estimation of treatment differences. The sample size of 2 × 75 patients was expected to provide sufficient power to reject the hypothesis of a large treatment difference under the assumption that the every 2-week schedule of cetuximab was non-inferior (see supplementary Methods, available at Annals of Oncology online). Exact two-sided 95% confidence intervals (CIs) according to Clopper-Pearson [31] were determined for ORR, and the stratified Cochran-Mantel-Haenszel (CMH) procedure was applied to estimate the odds ratio and associated 95% CI. Kaplan-Meier methods were used to estimate median PFS and OS and corresponding rates at various time points, including two-sided 95% CI [32] . Differences in PFS and OS between the two arms were compared using the stratified log-rank test, and Cox proportional hazard methods were applied to estimate the hazard ratio [HR] .
Explorative multivariate analysis for PFS and OS was carried out using a Cox proportional hazard model to investigate the impact of confounding factors and to test the difference between the treatment arms adjusted for significant confounding factors.
results patients
Between September 2007 and September 2009, 163 patients were randomized at 22 sites in 12 countries. Of these, 152 eligible patients comprised the KRAS wild-type population; patient disposition is shown in Figure 1 . Patient demographics and characteristics at baseline were generally comparable; however, more patients were ≥65 years old and more had colon tumors in the cetuximab every second week compared with the cetuximab weekly arm (Table 1 ). BRAF mutations (two in the cetuximab q1w arm and one in the cetuximab q2w arm) or with KRAS mutated tumors (three in both treatment arms) were excluded from the primary analysis following a protocol amendment to the study eligibility criteria. Other, in the FOLFOX4 + cetuximab weekly arm versus FOLFOX4 + cetuximab every second week arm included patients: temporarily lost to the follow up (1 versus 2), lost to the follow up (0 versus 1), received prior chemotherapy for mCRC (1 versus 0); had stable disease but increasing toxicity (1 versus 0) and had suspicion of progressive disease (0 versus 1). q1w, weekly; q2w, every second week.
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were detected in 14 of 148 (9%) evaluable patients with KRAS wild-type tumors. The number of patients with KRAS/BRAF wild-type tumors was comparable between the weekly cetuximab and every second week arms, 68 of 72 (94%) versus 66 of 76 (87%).
treatment exposure
The median duration of cetuximab treatment in the weekly versus every second week regimens was similar ( Table 2 ). The relative dose intensity (RDI) ≥80% was achieved for 79% of patients in each arm. More patients had dose reductions in the cetuximab every second week arm, while slightly more patients had treatment delays in the cetuximab weekly arm.
In the cetuximab weekly versus every second week arms: the duration of chemotherapy treatment was similar as were RDIs ≥80% achieved for oxaliplatin, folinic acid, bolus-FU and continuous infusion 5-FU; dose reductions occurred in 27% and 35% of patients, respectively, and treatment delays were comparable.
treatment activity
Treatment activity is summarized in Table 3 . The ORR was higher in patients in the cetuximab every second week versus original articles Annals of Oncology weekly arm (62% versus 53%), the difference was 9% (95% CI -7-25), which was not statistically significant. DCRs and rates of progressive disease were similar in both arms. In total, four (5%) patients in the cetuximab weekly arm and eight (10%) in the cetuximab every second week arm underwent R0 resection. The median observation time for PFS in the cetuximab weekly and every second week arms was 31.3 months (95% CI 30.2-36.7) and 28.7 months (95% CI 21.8-33.2), respectively; PFS (median 9.5 versus 9.2 months; HR = 0.92) and OS (median 25.8 versus 23.0 months; HR = 0.86) were not markedly different between the two arms (Table 3; Figure 2 ).
Subgroup analysis of ORRs revealed some noteworthy associations, although these findings should be treated with caution due to the small numbers of patients in some of the subgroups. The ORR was higher in patients ≥65 years old (57% versus 30%, odds ratio 3.11, 95% CI 0.97-10.00) and in those experiencing no acne-like rash (69% versus 38%, odds ratio 3.75, 1.16-12.12) in the cetuximab every second week versus weekly arm. No notable differences in subgroups between the treatment regimens for PFS and OS were reported. Further, there were no marked differences in treatment outcome between the arms in patients with EGFR detectable and undetectable tumors (supplementary Tables S1-3 , available at Annals of Oncology online).
Multivariate analysis identified independent prognostic factors for PFS (the number of organs involved and Karnofsky PS) and OS (the number of organs involved, Karnofsky PS, prior adjuvant therapy and sum of the longest diameter of target lesions). The HRs for PFS (1.01; 95% CI 0.69-1.47) and OS (0.99; 95% CI 0.66-1.51) did not indicate any effect of the cetuximab dosing regimen (weekly versus every second week) on these study end points when adjusted for the prognostic covariates (supplementary Table S4 , available at Annals of Oncology online).
Treatment activity in the cetuximab weekly and every second week arms was comparable in all treated patients (n = 161) and in those with KRAS and BRAF wild-type tumors (n = 134). Of note, in patients with KRAS and BRAF wild-type tumors, efficacy was slightly improved in both treatment arms compared with the other study populations (supplementary Table S5 , available at Annals of Oncology online).
safety
The most frequent AEs (MedDRA preferred terms) in the cetuximab weekly versus every second week arms were rash (64% versus 68%), neutropenia (41% versus 48%), diarrhea (35% versus 30%), fatigue (25% versus 18%), dermatitis acneiform (23% versus 21%), nausea (20% versus 21%) and pyrexia (13% versus 23%). In the cetuximab weekly and every second week arms, hypomagnesemia was reported in a total of two (3%) patients, including one with grade 3 hypomagnesemia, and in five (6%), including one with grade 3 hypomagnesemia. The incidences of grade 3/4 AEs and grade 3/4 AEs in the special AE categories were comparable between the treatment arms and were mainly grade 3 AEs (Table 4) . The most common grade 4 events (occurring in ≥5% of patients) were for grade 4 neutropenic events (reported as AE by the investigator or derived from laboratory neutrophil counts), which were similar between the cetuximab weekly and every second week arms (16% versus 18%). No grade 4 skin reactions, or acne-like rash, were reported. In the cetuximab every second week arm, one patient had a grade 4 infusionrelated reaction (IRR) and two had grade 3 neurotoxicity versus none in the weekly arm.
There was a higher reported frequency of AEs leading to dose reductions of cetuximab and/or chemotherapy in the cetuximab every second week arm versus weekly arm (30% versus 25%), mainly due to neutropenia leading to chemotherapy dose reduction in eight (10%) and three (4%) patients, respectively. FOLFOX4 was discontinued in five (7%) patients in the weekly cetuximab arm (one each for hyperglycemia, rash and hypotension, and two each for general disorders and Odds ratio and HRs are for FOLFOX4 + cetuximab q1w/FOLFOX4 + cetuximab q2w. CMH, Cochran-Mantel-Haenszel test; ORR, objective response rate; PFS, progression-free survival; q1w, weekly; q2w, every second week.
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administration site conditions and gastrointestinal disorders) and in seven (9%) in the every second week arm (one each for thrombocytopenia, bronchopneumonia, fall, dehydration, monoplegia, peripheral neuropathy and deep vein thrombosis).
In the weekly cetuximab and every second week arms where FOLFOX4 was discontinued, cetuximab was also discontinued in two (one each duodenal ulcer and ileus) and three patients (one each for bronchopneumonia, dehydration and deep vein thrombosis), respectively. In addition, cetuximab alone was discontinued in three patients in the weekly cetuximab arm (one each for neutropenia, bronchopneumonia and nail disorder) and five patients in the every second week arm (one original articles Annals of Oncology for hypersensitivity and four for skin and subcutaneous disorders). Forty-five (60%) patients in the weekly cetuximab arm and 49 (64%) in the every second week arm had died; disease progression and disease-related complications were responsible for the majority of these patient deaths (93% versus 86%). Seven patients died on-treatment or within 30 days of the last dose of study treatment; two ( progressive disease) in the weekly cetuximab arm and five in the every second week arm (one progressive disease, two intercurrent or unrelated events, one sudden death and one related to chemotherapy).
discussion
Recent phase I study data suggest that cetuximab (500 mg/m 2 ) administered every second week as monotherapy or in combination with FOLFIRI has a manageable safety profile and is feasible in the first-line treatment of mCRC patients [19] . The safety and activity of this regimen in combination with irinotecan-based chemotherapy in pretreated patients with mCRC have been confirmed [20] [21] [22] [23] [24] [25] [26] . However, as far as we are aware, the combination of cetuximab every second week with oxaliplatin-based chemotherapy in the first-line treatment of mCRC patients has not been previously investigated.
The primary end point of this randomized phase II study was therefore to determine the ORR in patients with KRAS wild-type mCRC treated with first-line FOLFOX4 plus cetuximab (500 mg/m 2 ) every second week compared with those treated with FOLFOX4 plus standard weekly cetuximab. With a higher, although not significantly different ORR (62% versus 53%), it can be suggested that the activity of the cetuximab every second week regimen is comparable with that containing standard weekly cetuximab in this setting. The observed ORR in the cetuximab every second week arm was similar to those reported for the experimental arms of randomized studies investigating standard cetuximab in combination with oxaliplatin-based chemotherapy (56-57%) in patients with KRAS wild-type mCRC [13, 14] . The ORR was also favorable when compared with those reported for the FOLFIRI plus cetuximab (500 mg/m 2 ) every second week regimen (57%) [19] or standard weekly cetuximab in combination with FOLFIRI (50-57%) in this setting [11, 14] .
Analyses of secondary end points revealed that DCR (87%), PFS (HR, 0.92) and OS times (HR, 0.86) were comparable in the cetuximab weekly and every second week arms. When adjusted for relevant baseline prognostic factors in multivariate analyses, the HRs for PFS and OS were 1.01 and 0.99, respectively, underlining the similarity of the two regimens. The median PFS (9.5 and 9.2 months) and OS (25.8 and 23.0 months) times reported in this study for the weekly and every second week regimens, respectively, were consistent with previous reports for standard weekly cetuximab in combination with oxaliplatin-based regimens [13, 14] .
Baseline characteristics were generally balanced between the treatment arms; however, there were more patients ≥65 years old and more with colon tumors in the cetuximab every second week versus the weekly cetuximab arm, but neither factors were identified as prognostic for PFS or OS. The subgroup analysis confirmed the activity of weekly cetuximab and every second week regimens in combination with standard chemotherapy in both EGFR detectable and undetectable tumors [33] [34] [35] .
Exposure to cetuximab was slightly higher in the every second week than the weekly regimen, which may indicate a better compliance for every 2-week infusion visits than for weekly administration. This did not affect the overall planned dose of cetuximab delivered to patients. The frequency of AEs leading to dose reductions of cetuximab and or chemotherapy (mainly due to neutropenia leading to chemotherapy dose reduction) was slightly higher in the every second week regimen. However, overall there was no impact of the cetuximab every second week regimen on the delivery of FOLFOX4 compared with the weekly cetuximab regimen. The incidences of grade 3/4 AEs and grade 3/4 AEs in the special AE categories were similar for the two treatment arms and were typical of those associated with exposure to cetuximaband oxaliplatin-based chemotherapy [13, 14, 19] . The higher single dose of cetuximab in the every second week regimen did not lead to any increased incidence of allergic reactions or IRR.
Treatment efficacy in the cetuximab weekly and every second week arms was comparable in all treated patients (n = 161). The KRAS wild-type population was found to contain patients with BRAF-mutated tumors (9%). BRAF tumor mutations are strongly associated with poor prognosis in mCRC, including those treated with EGFR monoclonal antibodies [11, [36] [37] [38] . After excluding BRAF-mutated tumors from the analysis, no marked differences in treatment efficacy between the cetuximab-containing regimens were found, which as expected was improved in both arms in this population. In summary, in this study, the combination of cetuximab every second week with FOLFOX4 demonstrated activity and a manageable safety profile comparable with that observed for FOLFOX4 plus standard weekly cetuximab in the first-line treatment of patients with KRAS wild-type mCRC. The introduction of an every second week dosing regimen for cetuximab may provide treatment flexibility in this setting when combined with chemotherapy regimens of similar or longer durations.
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